Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2013
11/12/2013US8580313 Fexofenadine microcapsules and compositions containing them
11/12/2013US8580310 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
11/12/2013US8580309 Antimicrobial mixtures
11/12/2013US8580308 Modafinil pharmaceutical compositions
11/12/2013US8580304 Pharmaceutical composition
11/12/2013US8580303 Gastric retained gabapentin dosage form
11/12/2013US8580300 Pharmaceutical formulation for treating the upper digestive tract
11/12/2013US8580297 Components for producing amphoteric liposomes
11/12/2013US8580296 Pharmacokinetics of S-adenosylmethionine formulations
11/12/2013US8580295 Carbohydrates mixture
11/12/2013US8580293 Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
11/12/2013US8580292 Sustained release intraocular implants and methods for treating ocular vasculopathies
11/12/2013US8580284 Oil-based cosmetic preparation
11/12/2013US8580278 Nutraceutical composition and methods for preventing or treating multiple sclerosis
11/12/2013US8580245 Compositions and methods for treating and preventing cardiomyopathy and heart disease
11/12/2013US8580244 Cyclodextrin-based polymers for therapeutics delivery
11/12/2013US8580243 Cyclodextrin-based polymers for therapeutics delivery
11/12/2013US8580242 Cyclodextrin-based polymers for therapeutics delivery
11/12/2013US8580241 Glycerol group-containing organopolysiloxane, cosmetic, and method for producing glycerol group-containing organopolysiloxane
11/12/2013US8580240 Compounds and methods for reducing the occurrence of post-surgical adhesions
11/12/2013US8580239 Skin grafting devices and methods
11/12/2013US8580235 Hair cosmetic
11/12/2013US8580231 Compositions and methods comprising magnetic resonance contrast agents
11/12/2013CA2752981C Indole derivatives as crth2 receptor antagonists
11/12/2013CA2733509C Antimicrobial silver solutions
11/12/2013CA2714357C Mutations in neuronal gene sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus
11/12/2013CA2708418C Oxazolidinones for the treatment and/or prophylaxis of heart failure
11/12/2013CA2706351C Arginine salts and their uses for the treatment of illnesses in the oral cavity
11/12/2013CA2692862C Stable compositions
11/12/2013CA2684592C Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine
11/12/2013CA2680017C Compositions and methods relating to novel compounds and targets thereof
11/12/2013CA2675419C Heterocyclic-substituted piperidine compounds and the uses thereof
11/12/2013CA2673334C Oral extended-release composition
11/12/2013CA2651206C Bivalent smac mimetics and the uses thereof
11/12/2013CA2632780C Combination of r,r-glycopyrrolate, rolipram, and budesonide for the treatment of inflammatory diseases
11/12/2013CA2628508C Use of fenofibrate or a derivative thereof for preventing diabetic retinopathy
11/12/2013CA2623822C 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
11/12/2013CA2621836C Isoquinolines as igf-1r inhibitors
11/12/2013CA2621486C Acute treatment of social phobia
11/12/2013CA2618708C Therapeutic agent and treatment method for ameliorating uremia
11/12/2013CA2615669C Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
11/12/2013CA2614639C Pharmaceutical composition for treatment of blood clotting disorder
11/12/2013CA2611474C Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
11/12/2013CA2606851C Composition and method for treating nosebleeds
11/12/2013CA2606683C 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility
11/12/2013CA2604038C New tricyclic angiotensin ii agonists
11/12/2013CA2599649C Drug formulations having controlled bioavailability
11/12/2013CA2599290C Ketoprofen sis adhesive for skin adhesive plaster
11/12/2013CA2597622C Crystalline base of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
11/12/2013CA2596884C Nandrolone 17.beta.-carbonates
11/12/2013CA2591948C Prodrugs of 2,4-pyrimidinediamine compounds and their uses
11/12/2013CA2591056C Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
11/12/2013CA2581831C Pharmaceutical compositions comprising levetiracetam and process for their preparation
11/12/2013CA2580619C Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
11/12/2013CA2576589C Pharmaceutical formulation comprising an antibiotic, a triazole and a corticosteroid
11/12/2013CA2576156C Use of xenon as neuroprotectant in a neonatal subject
11/12/2013CA2575029C Novel biaromatic compounds which activate receptors of ppar type and their use in cosmetic or pharmaceutical compositions
11/12/2013CA2567401C Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
11/12/2013CA2565250C Cysteamines for treating complications of hypercholesterolemia and diabetes
11/12/2013CA2557999C Methods and compositions for treatment of ion imbalances
11/12/2013CA2549652C Cd40 antibody formulation and methods
11/12/2013CA2548281C Method of preparation of mixed phase co-crystals with active agents
11/12/2013CA2537093C Compound capable of binding s1p receptor and pharmaceutical use thereof
11/12/2013CA2490516C Honey-based skin care preparation
11/12/2013CA2477012C Anti-a.beta. antibodies and their use
11/12/2013CA2471924C Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases, and for modulation of cell survival and/or death
11/12/2013CA2466701C Neuroprotective use of cyclic prolyl glycine
11/12/2013CA2448379C Calorically dense liquid oral supplement
11/12/2013CA2448022C Compositions for protein delivery via the pulmonary route
11/07/2013WO2013166503A1 Broad antiviral therapy with membrane modifying oxysterols
11/07/2013WO2013166502A1 Regulation of cardiac sodium channels by sirt1 and sirt1 activators
11/07/2013WO2013166487A1 Highly penetrative nanocarriers for treatment of cns disease
11/07/2013WO2013166468A1 Compositions and methods for treating neurodegenerative diseases
11/07/2013WO2013166449A2 Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
11/07/2013WO2013166438A1 Substrates and inhibitors of prolyl oligopeptidase and fibroblast activation protein and methods of use
11/07/2013WO2013166436A1 Pharmaceutical nanoparticles showing improved mucosal transport
11/07/2013WO2013166431A1 Lipids that increase insulin sensitivity and methods of using the same
11/07/2013WO2013166422A1 Compositions and methods for treating autism and autism spectrum disorder
11/07/2013WO2013166421A1 Melanoma chemoprevention
11/07/2013WO2013166413A2 Compositions and methods for increasing neurotrophic peptides
11/07/2013WO2013166366A1 Cul4b as predictive biomarker for cancer treatment
11/07/2013WO2013166319A1 Macrocyclic and peptidomimetic compounds as broad-spectrum antivirals against 3c or 3c-like proteases of picornaviruses, caliciviruses and coronaviruses
11/07/2013WO2013166307A2 N,n'-di-1 naphthylguanidine hcl (nagh) and n,n'-di-p-nitrophenylguanidine hcl (nad) treatment for stroke at delayed timepoints
11/07/2013WO2013166296A1 A dual met - vegf modulator for treating osteolytic bone metastases
11/07/2013WO2013166295A1 Treating neural disease with tyrosine kinase inhibitors
11/07/2013WO2013166282A2 Methods and compositions for treating bacterial infection
11/07/2013WO2013166246A2 Formulation and method to induce a deep state of relaxation
11/07/2013WO2013166206A1 A prenylated anthracenone polyketide as an immunosuppressant
11/07/2013WO2013166198A1 Antimicrobial polyurethane materials and methods of forming and using same
11/07/2013WO2013166180A1 Methods for the treatment of overactive bladder
11/07/2013WO2013166177A2 Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation
11/07/2013WO2013166176A1 Fatty acid conjugates of statin and fxr agonists; compositions and method of uses
11/07/2013WO2013166166A1 Use of high dose laquinimod for treating multiple sclerosis
11/07/2013WO2013166110A1 Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms)
11/07/2013WO2013166040A1 S-fta and s-fta analogues capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular degeneration, stargardt disease, and other retinal disease characterized by excessive lipofuscin accumulation
11/07/2013WO2013166037A1 Non-retinoid antagonists for treatment of eye disorders
11/07/2013WO2013166034A1 Methods for treatment of pelvic pain and / or comorbid conditions
11/07/2013WO2013166015A1 Ror modulators and their uses
11/07/2013WO2013166013A1 Ror modulators and their uses
11/07/2013WO2013165973A1 Combination treatment of multiple myeloma
1 ... 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 ... 7860